Real-World data: mavacamten shows promise for heart condition in canadian patients

NCT ID NCT06338202

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten as part of routine care. Researchers reviewed patient charts to see if the drug improved heart function and symptoms. The goal was to understand how mavacamten performs outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mavacamten (a drug to relax the heart muscle)
What this could lead to: If results are positive, this could confirm that mavacamten is effective in everyday practice, supporting its continued use for obstructive hypertrophic cardiomyopathy.
What could go wrong: This is a small, retrospective survey (115 patients) without a control group, so results may not apply to all patients. It only describes outcomes, not proving cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)

Contacts and locations

Locations

London Health Science Centre (LHSC)

London, Ontario, N6A 5A5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.